Chief Executive Officer Dwight Egan is slated to deliver a formal presentation at the W New York – Times Square, located at 1567 Broadway. Following the address, Egan will conduct a question-and-answer session to address inquiries about the company’s current portfolio and strategic direction. Participants unable to attend in person may access the proceedings via a live online webcast, for which registration is currently open.

Co-Diagnostics continues to focus on its patented platform for the development of nucleic acid-based diagnostic tests. Beyond its standard diagnostic operations, the company is actively working on its Co-Dx PCR at-home and point-of-care testing systems, though these remain subject to ongoing regulatory review. The event serves as a platform for stakeholders to gain insight into the firm's progress in both infectious disease detection and broader genetic marker identification applications.